Bavarian Nordic A/S has partnered with the Pan American Health Organization (PAHO) to facilitate equitable access to the its monkeypox vaccine for countries in Latin America and the Caribbean. Deliveries of the vaccines are expected to begin in September.
 
The vaccines will be made available to those countries that participate in PAHO’s Revolving Fund for Access to Vaccines – a technical cooperation mechanism established more than 40 years ago to support national immunization programs, pooling resources from participating PAHO member countries across the Americas to procure vaccines and related supplies.
 
Paul Chaplin, president and CEO of Bavarian Nordic said: “Monkeypox is a global health challenge that has prompted health authorities worldwide to respond, and we are pleased to work with PAHO to ensure access to vaccines for its member states in the Americas. With the agreement, we have now helped to secure access to our vaccine in more than 70 countries globally, representing the vast majority of affected regions outside endemic areas. While the global supply is currently limited, we are working diligently to increase our manufacturing capacity and have taken steps to partner with other companies to rapidly produce more vaccines to help combat the outbreak.”
 
Bavarian Nordic maintains its guidance for 2022 as this order has already been included in the upgraded financial expectations, as communicated on July 18, 2022.